Kuldev Singh is Professor of Ophthalmology and Director of the Glaucoma Service at the Stanford University School of Medicine . He received his MD and MPH degrees from the Johns Hopkins University and was a Dana Foundation Fellow at the Wilmer Eye Institute. Following residency training at the Casey Eye Institute, OHSU and a Heed Foundation Clinical Glaucoma Fellowship at the Bascom Palmer Eye Institute, Dr. Singh joined the Stanford faculty in 1992.
Dr. Singh has published over 250 papers, book chapters, monographs and abstracts including more than 125 original peer-reviewed articles and delivered more than 350 invited lectures on six continents. He has edited two textbooks and served on the editorial boards of ten ophthalmic publications. Dr. Singh’s current research interests include glaucoma and cataract surgical trials, epidemiology, genetics as well as health care delivery in underserved communities in the United States and overseas.
His clinical practice focuses on the medical, laser and surgical management of glaucoma and cataract. Dr. Singh has served as President of the American Glaucoma Society, Chair of the Board of Directors of the Glaucoma Research Foundation as well as Executive Vice President, the Chief Executive position, for the World Glaucoma Association. He is a member of the United States FDA Advisory Committee on Ophthalmic Devices and previously served as a Chair and Methodologist for the Ophthalmic Technology Assessment Panel of the American Academy of Ophthalmology.
How We Met
Keith and I are both alumni of the Bascom Palmer Eye Institute Fellowship Program in Miami, FL. For the two decades that ARVO was held in Ft. Lauderdale, Don Budenz, who was my co-fellow at Bascom Palmer in 1991-92 and longtime friend thereafter, hosted a reunion party of former fellows at his North Miami home during the meeting. Keith and I regularly saw each other at these dinners and also at investigator meetings for numerous surgical glaucoma studies that were held at ARVO and AAO.
Keith and I shared a common view of glaucoma practice and he became my go-to person for glaucoma care in Europe. Keith took great care of friends and family members that were visiting London or were based anywhere in Europe. We also saw each other at the European Glaucoma Society meetings held in Florence, Berlin and Madrid.
Our relationship became stronger when Keith invited me to be one of the visiting speakers at the Moorfields Glaucoma meeting in January, 2011 where he was a great host during my three days in London. Besides being a terrific ophthalmologist, Keith had established a reputation for putting on creative meetings that were most enjoyable for both the speakers and the audience.
In May, 2012, while attending ARVO, Keith and I decided that there was a need for an Innovation Meeting in Europe. Partly due to regulatory hurdles in the United States, novel ophthalmic innovation was increasingly coming from Europe yet their was no European forum that brought together all stakeholders in moving the field forward. We believed that ideally, such a meeting should be driven by ophthalmologists, and include innovators, investors, regulators as well as clinicians. The most prominent European ophthalmic congress was ESCRS and we decided to have our first Ophthalmology Futures meeting just preceding the September, 2012 ESCRS meeting in Milan, Italy.
It was a daunting task to put together a fully funded new meeting in four months but Keith and I quickly realized that we complemented each other well in this project. The subsequent 2013 meeting in Amsterdam was larger and given the strong interest expressed by all stakeholders, we held a third such forum in Tokyo preceding the World Ophthalmology Congress in April, 2014. The Tokyo forum was particularly special as in addition to our usual showcase of new ophthalmic technology, we had panels that focused on using technology to improve eyecare in the developing world as well as on global regulatory issues in device approval.
Our fourth Ophthalmology Futures meeting in London 2014 was the best to date and our partnership continues to be most enjoyable.